Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)

ClinicalTrials.gov ID: NCT03217565

Public ClinicalTrials.gov record NCT03217565. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Single- and Multiple-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years Old

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objectives of this study are to describe the single-dose, and multiple dose pharmacokinetics (PK) of intravenous (IV) tedizolid phosphate, or a single dose oral suspension of tedizolid phosphate, when administered to pediatric participants, full-term neonates, and preterm neonates.

Study identification

NCT ID
NCT03217565
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
47 participants

Conditions and interventions

Eligibility (public fields only)

Age range
1 Day to 24 Months
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 5, 2019
Primary completion
Mar 17, 2023
Completion
Apr 5, 2023
Last update posted
Feb 10, 2025

2019 – 2023

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Arkansas Children's Hospital ( Site 1012) Little Rock Arkansas 72202
Children's Hospital of Orange County ( Site 1001) Orange California 92868
Sharp Memorial Hospital ( Site 1021) San Diego California 92123
Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 1022) Chicago Illinois 60611
Our Lady of the Lake Regional Medical Center. ( Site 1004) Baton Rouge Louisiana 70808
Saint Louis Children's Hospital ( Site 1020) St Louis Missouri 63110
Primary Children's Hospital ( Site 1000) Salt Lake City Utah 84113

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03217565, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 10, 2025 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03217565 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →